NCT04797442View on ClinicalTrials.gov

Effect of Akkermansia Muciniphila WST01 Strain in Overweight or Obese Patients With Type 2 Diabetes

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

November 9, 2022

Study Completion Date

March 31, 2024

Conditions
ObeseOverweightType 2 Diabetes
Interventions
DRUG

WST01 strain product

orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)

DRUG

placebo powder

orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)

Trial Locations (1)

200025

Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER